Pasithea Therapeutics Corp.
KTTA Nasdaq· Pharmaceutical Preparations
Last close · Oct 23, 2026
$0.40
KIRA · Stoqly’s AI analyst, in plain words
- Pasithea Therapeutics Corp. lost $20.4M in fiscal 2025.
Market cap
$13.0M
P/E
—
Revenue
—
Net income
−$20.4M
Free cash flow
—
Operating margin
—
Pasithea Therapeutics Corp. in 30 seconds · fiscal 2025
Does it make a profit?
−$20.4M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Pasithea Therapeutics Corp. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Pasithea Therapeutics Corp.
- CIK
- 0001841330
Pasithea Therapeutics Corp. · KTTA
Results and finances
The last 5 fiscal years. Amounts in USD.
| Fiscal year | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $0.0M | $0.5M | — | — | — |
| Revenue growth | — | 3,122.5% | — | — | — |
| Net interest income | −$0.0M | — | — | — | — |
| Gross margin | −14.6% | 76.7% | — | — | — |
| Operating margin | −29,850.3% | −2,587.1% | — | — | — |
| Net income | −$2.2M | −$13.9M | −$16.0M | −$13.9M | −$20.4M |
| Net margin | −14,394.0% | −2,864.1% | — | — | — |
| Diluted EPS | −$0.21 | −$1.76 | −$0.42 | −$12.69 | −$2.91 |
| Cash | |||||
| Cash from operations | −$3.2M | −$14.6M | −$12.8M | −$13.9M | −$15.2M |
| Capital expenditure | $0.0M | $0.1M | $0.0M | — | — |
| Free cash flow | −$3.2M | −$14.7M | −$12.8M | — | — |
| FCF margin | −21,162.9% | −3,014.6% | — | — | — |
| Share buybacks | — | — | $3.7M | — | — |
| Share count change | — | −87.9% | −2.8% | −10.6% | 541.5% |
| Debt and strength | |||||
| Cash and short-term investments | $53.0M | $33.1M | $16.3M | $6.9M | $55.2M |
| Shareholders' equity | $51.4M | $42.5M | $23.4M | $14.8M | $55.2M |
| Current ratio | 119.2x | 18.1x | 6.3x | 6.6x | 11.4x |
| Interest coverage | −9,014.8x | −125,890.0x | — | — | — |
| Returns and quality | |||||
| Return on equity | −4.2% | −29.7% | −48.4% | −72.8% | −58.4% |
| Return on tangible equity | −4.2% | −42.7% | −112.5% | −224.0% | −39.0% |
| Piotroski F-score | — | 3 | — | — | — |
| Altman Z'' | 34.2 | 18.0 | 4.0 | −1.4 | 11.0 |
Insiders bought, 12 months
$0.2M
4 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Pasithea Therapeutics Corp. · KTTA
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $0.40 a share, the company is worth $13.0M.
Source: SEC EDGAR XBRL filings (CIK 0001841330). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.